TABLE II.

Safety profile and resource use for treatment strategies

Strategy	Safety profile (adverse effects)	Clinical setting	Length of stay	Unplanned ICU admissiona	Typical PPEb	Immunosuppression
Hepatectomy	Major morbidity: 20% Mortality: 2%	Inpatient	3–6 Days	5%–10%	Yes	Relative: postoperative SIRS
Systemic therapy	Depends on regimen. Consider neutropenia and lymphopenia.	Outpatient	Recurrent visits (every 1–3 weeks)	Rare	Yes	Yes
Percutaneous ablation	4% Grade 3 events	Outpatient Inpatient (possible OR)	1 Day 1–2 Days	Rare	Yes	No
Ablative radiation therapy (SBRT)	6%–7% Grade 3 gastrointestinal events (if proximity to duodenum or stomach)	Outpatient	3–5 Daily visits	Rare	No	No
Intra-arterial liver embolization	15%–30% Pain, fatigue, vomiting	Outpatient Inpatient (possible OR)	1 Day (might require repeats, 4–6 weeks apart) 1–2 Days	Rare	Yes	No

^aExcludes routine planned postoperative admissions for monitoring.

^bThat is, mask, gown, gloves—PPE requirements for usual care (could vary during COVID-19 pandemic, depending on institutional protocols).

ICU = intensive care unit; PPE = personal protective equipment; SIRS = systemic inflammatory response syndrome; OR = operating room; SBRT = stereotactic body radiation therapy.